There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > HMGB1


Brief Information

Name:High Mobility Group Proteins B1
Target Synonym:Heparin-Binding Protein p30,High Mobility Group Box 1,High-Mobility Group (Nonhistone Chromosomal) Protein 1,Sulfoglucuronyl Carbohydrate Binding Protein,High Mobility Group Protein B1,High Mobility Group Protein 1,Amphoterin,Box Protein 1, High Mobility
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:0
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
HM1-M52H6 Mouse Mouse HMGB1 Protein, His Tag
HM1-H5255 Human Human HMGB1 Protein, Mouse IgG2a Fc Tag, low endotoxin
HM1-H5220 Human Human HMGB1 Protein, His Tag

Part of Bioactivity data

HM1-H5255-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human HMGB1, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. HM1-H5255) stimulates production of TNF-α in Raw-246.7 cells. The EC50 for this effect is 13.18 μg/mL (Routinely tested).

Synonym Name



High-mobility group protein B1 (HMGB1) is also known as high-mobility group protein 1 (HMG-1) and amphoterin, is a member of the HMGB family consisting of three members, HMGB1, HMGB2 and HMGB3. HMGB1 is a non-histone architectural chromosomal protein ubiquitously present in all vertebrate nuclei and binds double-stranded DNA without sequence specificity. The mechanism of inflammation and damage is binding to TLR4, which mediates HMGB1-dependent activation of macrophage cytokine release. This positions HMGB1 at the intersection of sterile and infectious inflammatory responses. HMGB1 has been studied as a DNA vaccine adjuvant and a target for cancer therapy.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Dociparstat sodium ODSH; CX-01; PGX-100; PGX-ODSH-2013-AML-1 Phase 3 Clinical Paringenix Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Leukemia, Myeloid, Acute; Protein-Losing Enteropathies; Pulmonary Disease, Chronic Obstructive; Acute Lung Injury Details

This web search service is supported by Google Inc.